[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625674":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":47,"collaborators":24,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":24,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":24,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":24,"overallStatus":68,"whyStopped":24,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Cultech Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active","ACTIVE_COMPARATOR","Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day",[13],"Dietary Supplement: Lab4S",{"label":15,"type":16,"description":15,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Dietary Supplement: Placebo",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT","Lab4S",[9],null,{"type":21,"name":15,"description":15,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Maya Dabcheva","CONTACT","+359887113036","maya.dabcheva@comac-medical.com",[34],{"facility":35,"status":24,"city":36,"state":24,"zip":24,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Comac Medical","Sofia","Bulgaria","BG",{"type":40,"coordinates":41},"Point",[42,43],23.32415,42.69751,{"lat":43,"lon":42},[46],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},{"type":48,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100625674","probiotics-antibiotics-and-the-post-antibiotic-microbiota-100625674",false,"NCT07425704","Probiotics, Antibiotics and the Post-Antibiotic Microbiota","Inclusion Criteria:\n\n1. Adults, aged 18-40.\n2. Been prescribed an oral dose of cephalosporin antibiotic lasting 5 - 10 days.\n3. Willing to provide stool samples and, for women, vaginal samples.\n4. Willing to avoid consumption of any other probiotic capsules\u002Ftablets during the study.\n\nExclusion Criteria:\n\n1. If antibiotics prescribed are intended to treat any gastrointestinal or vaginally related issue.\n2. Any antibiotic intake within the last 3 months.\n3. Immunodeficient or undergoing immunosuppressive therapy.\n4. Currently diagnosed with diabetes\u002Fcardiovascular disease\u002Fcancer\u002Fdementia.\n5. Any unexplained loss of weight in recent months.\n6. Known to be pregnant or \\\u003C3 months postpartum.","ALL","18 Years","40 Years",{"count":59,"type":60},50,"ESTIMATED","INTERVENTIONAL",[63],"NA","Antibiotic therapy can cause gastrointestinal dysbiosis and this study will assess the impact of probiotic supplementation on microbiological composition and functionality pre- and post- antibiotic therapy",[66,67],"Probiotic","Microbiome","NOT_YET_RECRUITING","2026-03-16",{"date":71,"type":72},"2026-03-18","ACTUAL",{"date":74,"type":60},"2026-04-13",{"date":76,"type":60},"2026-12-01",{"name":5,"class":6},1]